stoxline Quote Chart Rank Option Currency Glossary
  
Ocular Therapeutix, Inc. (OCUL)
8.4  -0.03 (-0.36%)    07-16 10:51
Open: 8.535
High: 8.68
Volume: 362,838
  
Pre. Close: 8.43
Low: 8.33
Market Cap: 1,301(M)
Technical analysis
2024-07-16 10:20:54 AM
Short term     
Mid term     
Targets 6-month :  10.13 1-year :  11.84
Resists First :  8.68 Second :  10.13
Pivot price 7.09
Supports First :  6.27 Second :  4.78
MAs MA(5) :  7.95 MA(20) :  6.81
MA(100) :  7.24 MA(250) :  5.17
MACD MACD :  0.5 Signal :  0.3
%K %D K(14,3) :  94.9 D(3) :  95.2
RSI RSI(14): 79.8
52-week High :  11.31 Low :  1.99
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ OCUL ] has closed Bollinger Bands are 4.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.49 - 8.52 8.52 - 8.55
Low: 8.02 - 8.05 8.05 - 8.09
Close: 8.37 - 8.42 8.42 - 8.47
Company Description

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Headline News

Mon, 15 Jul 2024
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable - Simply Wall St

Fri, 12 Jul 2024
The one-year returns have been notable for Ocular Therapeutix (NASDAQ:OCUL) shareholders despite underlying losses increasing - Yahoo Finance

Wed, 10 Jul 2024
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 5.7% - MarketBeat

Wed, 10 Jul 2024
Ocular Therapeutix™ Announces Late-Breaking Abstract of - GlobeNewswire

Mon, 08 Jul 2024
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sun, 23 Jun 2024
Institutional investors control 64% of Ocular Therapeutix, Inc. (NASDAQ:OCUL) and were rewarded last week after stock increased 8.7% - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 155 (M)
Shares Float 126 (M)
Held by Insiders 0.7 (%)
Held by Institutions 80.6 (%)
Shares Short 23,370 (K)
Shares Short P.Month 21,220 (K)
Stock Financials
EPS -1.13
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.64
Profit Margin -192.7 %
Operating Margin -214 %
Return on Assets (ttm) -17.2 %
Return on Equity (ttm) -55.2 %
Qtrly Rev. Growth 10.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.38
EBITDA (p.s.) -0.57
Qtrly Earnings Growth 0 %
Operating Cash Flow -84 (M)
Levered Free Cash Flow -58 (M)
Stock Valuations
PE Ratio -7.57
PEG Ratio 0
Price to Book value 3.2
Price to Sales 21.92
Price to Cash Flow -15.6
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android